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0.63 ± 0.16 and 0.64 ± 0.46, respectively, for the treatment 
group, and 0.06 ± 0.15 and 0.06 ± 0.28, respectively, for the 
control group (p < 0.001). Serum insulin-like growth fac-
tor (IGF-1) and insulin-like growth factor binding protein-3 
(IGFBP-3) increased significantly in the treatment group at 
week 26 compared to baseline. However, the SDS for body 
mass index (BMI) at 26 weeks did not change significantly 
in either group.  Growtropin®-II was well tolerated and safe 
over 1 year of treatment.
Conclusions One-year GH treatment for prepubertal chil-
dren with ISS demonstrated increased annualized velocity, 
height and weight SDSs, and IGF-1 and IGFBP-3 levels, 
with a favorable safety profile. Further evaluations are 
needed to determine the optimal dose, final adult height, 
and long-term effects of ISS treatment.
Abstract 
Purpose Several studies have evaluated the effects of 
growth hormone (GH) on auxological and biochemical 
parameters in children with non-GH-deficient, idiopathic 
short stature (ISS). This study evaluated the efficacy and 
safety of  Growtropin®-II (recombinant human GH) in 
Korean patients with ISS.
Methods This was a 1-year, open-label, multicenter, phase 
III randomized trial of  Growtropin®-II in Korean patients 
with ISS. In total, 70 prepubertal subjects (39 males, 31 
females) between 4 and 12 years of age were included in the 
study. All patients were naive to GH treatment.
Results Annual height velocity was significantly higher in 
the treatment group (10.68 ± 1.95 cm/year) than the con-
trol group (5.72 ± 1.72, p < 0.001). Increases in height and 
weight standard deviation scores (SDSs) at 26 weeks were 
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Introduction
Children with idiopathic short stature (ISS) are a heterogene-
ous group; there are many unidentified causes of short stat-
ure, and wide variation in causative biological factors, the 
extent of bone-age delay, and timing of puberty [1]. ISS is 
defined as a height more than two standard deviations (SD) 
below the age-, sex-, and population-matched mean, despite 
a normal or increased response to growth hormone (GH) on 
the GH stimulation test, and in the absence of any systemic, 
endocrine or metabolic disease, chromosome abnormality, 
or other disease that may compromise growth [2, 3].
GH therapy has been approved by the US Food and Drug 
Administration (FDA) for patients with GH deficiency 
(GHD, 1985), chronic renal insufficiency (1993), Turner 
syndrome (TS, 1997), or Prader-Willi syndrome (PWS, 
2000), for children with a history of intrauterine growth 
restriction (IUGR) [small for gestational age (SGA), 2001], 
short stature with homeobox-containing gene deficiency 
(2006), or Noonan syndrome (NS, 2007) [4–6]. In 2003, 
the FDA extended the indications for GH therapy to include 
children with ISS who are > 2.25 SD below the mean height, 
and who are unlikely to catch up in height [7].
Studies evaluating GH therapy in children with ISS 
for 4–7 years revealed an increase in adult height (AH) 
of 3–6 cm [1, 3, 8, 9], and a safety profile similar to other 
GH indications [1]. Although the mean height increased in 
response to GH therapy, there was significant variability 
in individual growth responses, including no measurable 
increase in height standard deviation scores (Ht SDSs) in 
some patients [9, 10].
The present study was a 1-year, open-label, multi-center, 
randomized controlled trial (RCT) of recombinant human 
GH (rhGH) administered to prepubertal Korean children 
with ISS. We comprehensively analyzed the efficacy and 
safety of GH therapy.
Materials and methods
Subjects
Inclusion criteria for the study were as follows: prepubertal 
children [evaluated according to the Tanner classification: 
testicular volume of 4 cc or less (boys) and Tanner stage I 
breast development (girls)]; height below the third percentile 
for a Korean population of the same chronological age (CA) 
and sex; one or more peak GH levels of 10 ng/ml or above, 
confirmed by GH stimulation testing in those taking two 
or more of clonidine, glucagon, insulin, and levodopa, and 
normal karyotype (female); older than 4 years of age with a 
bone age (BA) of < 11 years (girls) or < 13 years (boys), and 
a disparity of 3 years or less between BA and chronological 
age; naive to GH therapy, and; normal thyroid function (or 
normalized after hormone therapy).
Exclusion criteria were as follows: hypopituitarism, 
GHD, chronic renal failure, SGA, IUGR, premature birth 
(gestational age of ≤ 36 weeks), congenital infections, TS, 
PWS, NS, Russell-Silver syndrome, Seckel syndrome, Down 
syndrome, Cushing’s syndrome, or other chromosomal 
abnormalities; congenital or chronic disease; currently 
receiving a drug that may affect the secretion and action of 
GH (such as estrogen, androgen, anabolic steroid, corticos-
teroid, or methylphenidate); and a history of hypersensitivity 
to GH.
Prior to the screening test, based on consent forms 
approved by the Korean Ministry of Food and Drug Safety 
(MFDS, approval no.11886) and the institutional review 
board of each institution, informed consent was obtained 
from the subjects themselves and their legally authorized 
representatives (e.g., parents) by their own discretion.
Methods
Eligible children were given subcutaneous injections of 
rhGH at a dose of 1.11 IU (0.37 mg)/kg/week (the stand-
ard dose approved by the FDA), divided into six to seven 
doses per week, for 52 weeks. The rhGH  (Growtropin®-II, 
DA-3002) was provided by Dong-A ST Ltd. (Seoul, Korea). 
Subjects randomized to the treatment group (n  =  36) 
received rhGH from week 0 to week 52, while subjects rand-
omized to the control group (n = 34) were observed without 
treatment from week 0 to week 26 and received the rhGH 
from week 27 to week 52. Randomization was performed at 
a 1:1 ratio using a block method. Subjects were required to 
visit their study site at weeks 13, 26, 39 and 52 for measure-
ments of height and weight; assessment of levels of insulin-
like growth factor 1 (IGF-1), insulin-like growth factor bind-
ing protein 3 (IGFBP-3), and hemoglobin A1C; evaluation 
of thyroid function; and other laboratory tests. IGF-1 and 
IGFBP-3 were measured via CLIA using a Siemens Immu-
lite 2000 XPi immunoassay system, and Siemens reagents, 
in our central laboratory. Subjects also completed question-
naires exploring drug compliance and adverse events, either 
in person during visits or via telephone between visits (at 
weeks 6, 19, 32, and 45). Subjects in the control group con-
tinued to receive therapy for an extra 6 months at the end of 
the study, during which they attended a follow-up visit for 
safety evaluation.
The pubertal stage was evaluated by a pediatric endocri-
nologist at each visit. BA and anti-GH antibody levels were 
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determined at baseline and at weeks 26 and 52. GH antibody 
levels were measured with the aid of a GH Ab ELISA Kit 
(Wuhan EIAAB Science) and an ELx808™ Absorbance 
Microplate Reader (BioTeck), in our central laboratory. BA 
was measured by a single pediatric endocrinologist, based 
on X-rays of the left hand and wrist using the Greulich-Pyle 
method.
Outcome variables
The primary efficacy endpoint was the difference in annual 
height velocity (cm/year) at week 26 between the treatment 
and control groups. Secondary efficacy endpoints were the 
differences in Ht SDS, BA, IGF-1, and IGFBP-3 between 
the treatment and control groups at week 26, the difference 
in annual height velocity (cm/year) between weeks 0 and 52 
(treatment group) and weeks 27 and 52 (control group), and 
the difference in annual height velocity (cm/year) between 
weeks 0 and 26 (treatment group) and weeks 0 and 52 (treat-
ment group). The Ht SDS was calculated using the growth 
standard for Korean children and adolescents. Adverse event 
rates were summarized by system organ class (SOC) and 
preferred term (PT) using MedDRA software (ver.17.0; 
International Federation of Pharmaceutical Manufactur-
ers Associations, http://www.meddra.org). Investigators 
were instructed to report any adverse clinical or laboratory 
findings.
Statistical analysis
Statistical analysis was performed using SAS statistical soft-
ware (ver. 9.2, SAS Institute, Cary, NC, USA). Data are pre-
sented as mean ± SD, as minimum and maximum values for 
quantitative variables, mean ± SD for efficacy variables, and 
frequency and percentage for qualitative variables. Descrip-
tive statistics were used to summarize participant baseline 
characteristics. Efficacy was analyzed using a two-sample t 
test or the Wilcoxon rank sum test, depending on the results 
of the Shapiro–Wilk normality test; we assessed differences 
between the control and treatment groups. The Wilcoxon 
rank sum test was used to evaluate the difference in adher-
ence between the treatment groups of the clinical trial. 
Safety analysis was performed by reference to both adverse 
events and laboratory data. Adverse events were summarized 
descriptively by SOC and PT, as well as by severity and rela-
tionship to the study drug. Differences in laboratory values, 
analyzed separately in normal and abnormal range groups, 
were determined using McNemar’s test. In cases where the 
subject dropped out of the study, the annual height veloc-
ity (cm/year) was calculated using the height measured at 
the last visit. A p value less than 0.05 was considered to be 
statistically significant.
Results
Patient characteristics and auxological data at baseline
In total, 86 Korean subjects were recruited from 11 hospitals 
in February 2012, of whom 70 were enrolled in this study, 
which ended in April 2014. In total, 34 subjects were rand-
omized to the control group, and 36 to the treatment group. 
The distribution of subjects is shown in Fig. 1. Of the 70 
subjects, there were 39 boys (55.7%) and 31 girls (44.3%); 
64 (91.7%) of the 70 subjects completed the 26-week treat-
ment, among whom 63 (90.0%) completed the study. The 
most common reason for premature discontinuation was 
‘withdrawal of consent’ (n = 5), followed by ‘protocol vio-
lation’ (n = 2). The mean chronological age of the subjects 
was 6.96 ± 2.07 years (range: 4.0–12.1 years). The mean 
BA was 5.32 ± 2.24 years (range: 2.5–11.00 years). The 
mean height was 108.31 ± 10.76 cm (-2.37 ± 0.50 SDS), 
the mean weight was 18.34 ± 4.28 kg (2.03 ± 0.99 SDS), 
and the mean body mass index (BMI) was 15.45 ± 1.43 
(-0.54 ± 0.97 SDS). The pretreatment height velocity did not 
differ significantly between the two groups. The subjects had 
no history of GH therapy before this study, and there was no 
significant group difference in demographic information or 
baseline characteristics (Table 1).
Efficacy results
The full analysis (FA) set was defined as all subjects who 
received at least one dose of the study drug and had at least 
one measurement of the primary efficacy endpoint after 
randomization. The per-protocol (PP) set was defined as 
all subjects who completed all 26 weeks of the study with-
out any major protocol violation. During the study period, 
major protocol violation occurred for one subject (2.9%) in 
the control group and six subjects (16.7%) in the treatment 
group. The violation types included inclusion/exclusion 
criteria violation, treatment compliance < 80%, continuous 
use of contraindicated drugs for ≥ 1 week, and more than 
three administration and dosage violations. The safety set 
consisted of 67 subjects (31 in the control group, 36 in the 
treatment group). The efficacy measures were analyzed in 
the FA set, which consisted of 68 subjects (32 in the control 
group and 36 in the treatment group), excluding 2 subjects 
who did not undergo primary efficacy evaluation after rand-
omization. The PP set included 61 subjects (31 in the control 
group, 30 in the treatment group).
The primary efficacy endpoint, annualized height veloc-
ity (cm/year) at week 26, was 5.72 ± 1.72 in the control 
group and 10.68 ± 1.95 in the treatment group, indicating 
a statistically significant difference (p < 0.001) (Fig. 2, 
Table 2). Regarding the secondary efficacy endpoints, the 
Ht SDS increased significantly from the baseline at week 
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Fig. 1  Flow of the distribution 
of subjects
Table 1  Baseline demographics of individuals with ISS
GH growth hormone, SDS standard deviation score
a Calculated using the modified LMS method suggested by the Korean Center for Disease Control and Prevention (CDC) and the Korean Pediat-
ric Society
Group Control (n = 34) Treatment (n = 36) Total (n = 70)
Category N (%), mean ± SD (minimum, maximum)
Male/female 17 (50.0)/17 (50.0) 22 (61.1)/14 (38.9) 39 (55.7)/31 (44.3)
Chronological age (years) 7.17 ± 2.34 (4.3, 12.1) 6.75 ± 1.79 (4.0, 11.0) 6.96 ± 2.07 (4.0, 12.1)
Bone age (years) 5.53 ± 2.62 (2.7, 11.0) 5.11 ± 1.84 (2.5, 11.0) 5.32 ± 2.24 (2.5, 11.0)
Height (cm) 109.18 ± 11.78 (92.87, 133.27) 107.49 ± 9.80 (89.93, 126.17) 108.31 ± 10.76 (89.93, 133.27)
Height  SDSa − 2.40 ± 0.40 (− 3.32, − 1.90) − 2.35 ± 0.58 (− 4.50, − 1.89) − 2.37 ± 0.50 (− 4.50, − 1.89)
Weight (kg) 18.73 ± 4.39 (13.7, 30.7) 17.97 ± 4.20 (10.5, 27.2) 18.34 ± 4.28 (10.5, 30.7)
Weight  SDSa − 1.95 ± 0.76 (− 4.03, − 0.52) − 2.11 ± 1.17 (− 6.02, − 0.02) − 2.03 ± 0.99 (− 6.02, − 0.02)
Body mass index (kg/m2) 15.55 ± 1.11 (12.65, 17.65) 15.36 ± 1.69 (12.98, 20.71) 15.45 ± 1.43 (12.65, 20.71)
Body mass index  SDSa − 0.45 ± 0.93 (− 2.96, 1.19) − 0.64 ± 1.01 (− 2.53, 2.22) − 0.54 ± 0.97 (− 2.96, 2.22)
Pretreatment height velocity 
(cm/year)
5.19 ± 1.17 (2.73, 7.25) 5.41 ± 1.50 (2.73, 8.74) 5.31 ± 1.34 (2.73, 8.74)
Peak GH level (ng/mL) 20.90 ± 14.66 (10.20, 91.00) 21.87 ± 16.88 (10.00, 88.00) 21.40 ± 15.74 (10.00, 91.00)
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26 in both the control and treatment groups (control group, 
p = 0.033; treatment group, p < 0.001). The difference in 
Ht SDS at week 26 relative to baseline was 0.06 ± 0.15 in 
the control group and 0.63 ± 0.16 in the treatment group, 
showing a statistically significant difference between the two 
groups (p < 0.001). These results indicate that short-term 
GH therapy can enhance growth velocity. Weight SDS at 
week 26 of the study increased compared to the baseline in 
both groups and the differences between the two groups were 
statistically significant (0.64 ± 0.46 in the treatment group 
and 0.06 ± 0.28 in the control group, p < 0.001); however, 
BMI SDS at week 26 did not change significantly in either 
group (0.12 ± 0.52 in the treatment group, − 0.03 ± 0.32 in 
the control group, p = 0.152). The BA advanced from week 
4 to week 26 in both groups (treatment group, p < 0.001; 
control group, p < 0.001). The mean differences between 
week 4 and week 26 were 0.39 ± 0.41 in the treatment group 
and 0.37 ± 0.41 in the control group, with no statistically 
significant difference between the two groups (p = 0.836). 
The BA was not too advanced for CA as the bone maturation 
rate (change in BA/change in CA) was 0.71 ± 0.79 in the 
treatment group and 0.74 ± 0.78 in the control group. Serum 
IGF-1 level in the treatment group increased significantly at 
week 26 compared to baseline levels (101.16 ± 42.34 ng/mL 
at baseline vs. 257.61 ± 83.63 ng/mL at week 26; p < 0.001). 
The differences in serum IGF-1 levels were 12.54 ± 29.95 
in the control group and 153.34 ± 67.60 in the treatment 
group, indicating a statistically significant difference 
between the two groups (p < 0.001). Serum IGFBP-3 level 
also increased significantly at week 26 compared to the base-
line (3.23 ± 0.83 ng/mL at baseline vs. 4.89 ± 0.74 ng/mL 
at week 26; p < 0.001). The mean differences in IGFBP-3 
between week 4 and week 26 were 0.62 ± 0.87 in the control 
group and 1.65 ± 0.76 in the treatment group, indicating a 
statistically significant difference in magnitude of change 
between the groups (p < 0.001).
The annual height velocity values were 10.48 ± 1.70 
(cm/year) after weeks 27–52 in the control group and 
10.17  ±  1.23 (cm/year) after weeks 0–52 in the treat-
ment group, showing no statistically significant difference 
(p = 0.423) (Table 3). The difference in annual height veloc-
ity in the treatment group, at week 52 versus week 26, was 
-0.78 ± 1.03 cm/year, which was a statistically significant 
difference (p < 0.001) despite being less than 1 cm/year. 
Analysis with the PP set revealed efficacy results similar to 
those of the FA set (data not shown).
Safety results
The follow-up set for additional safety evaluation at the end 
of the study consisted of 30 control group subjects only. 
The compliance rate was 97.65 ± 3.69% in the 26 weeks 
Fig. 2  Differences in annualized height velocity, height SDS, weight 
SDS, body mass index SDS, bone age, IGF-1 level, and IGFBP-3 
level at 26 weeks from baseline in the control and treatment groups. a 
annualized height velocity, b height SDS, c weight SDS, d body mass 
index SDS, e bone age, f IGF-1 level, g IGFBP-3 level. SDS standard 
deviation score, IGF-1 insulin-like growth factor-1, IGFBP-3 insulin-
like growth factor binding protein-3. *Two-sample t test. †Wilcoxon 
rank sum test
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after the non-treatment period in the control group and 
92.60 ± 21.00% over the 52 weeks in the treatment group. 
We found no statistically significant difference between the 
two groups (p = 0.446). One adverse drug reaction (ADR) 
occurred in one subject in the treatment group, while none 
occurred in the control group. The reported ADR was a 
mild rash. Three serious adverse events (SAEs) occurred 
in three different subjects. In the control group, one subject 
underwent an ophthalmologic operation for correction of 
strabismus during a non-treatment period. In the treatment 
group, one subject developed acute pharyngotonsillitis, and 
hypertrophy of the adenoids was observed in another sub-
ject. However, none of these events was related to the drug 
and all three subjects recovered without sequelae.
Among the 67 subjects, 21 (67.7%) children in the control 
group reported 71 adverse events and 25 (69.4%) children 
in the treatment group reported 78 adverse events (Table 4). 
The most common adverse event was infection, which was 
reported in 18 (58.1%) children in the control group and 
17 (47.2%) children in the treatment group. Upper respira-
tory tract infection, which was a frequently occurring event 
among the study population, comprised more than half of 
the adverse events. All remaining adverse events were mild.
No serious ADRs were reported and there was no with-
drawal due to adverse events. As for the clinical laboratory 
findings regarding blood chemistry and thyroid function, 
most of the parameters, except phosphorus level, did not 
show statistically significant within-group changes and 
were classified as changes from ‘outside the normal range’ 
to ‘normal’ (Table 5). Phosphorus levels were found to be 
equal to or close to the upper limit of the normal range, 
and were considered to not be clinically meaningful. The 
increases in anti-GH level at 26 weeks from baseline were 
Table 2  Differences in height, height velocity, height SDS, weight 
SDS, body mass index SDS, bone age, IGF-1, and IGFBP-3 at 
26 weeks from baseline in the control and treatment groups
SDS standard deviation score, IGF-1 insulin-like growth factor-1, 
IGFBP-3 insulin-like growth factor binding protein-3
a Two sample t test
b Wilcoxon rank sum test
c Paired t test
d Wilcoxon signed rank test
Group Control (n = 32) Treatment (n = 36) p value
Difference in
 Height (cm)
  Baseline 109.24 ± 12.26 107.61 ± 9.69
  Week 26 112.07 ± 11.99 112.87 ± 9.60
  Annualized 
height veloc-
ity (cm/year)
5.72 ± 1.72 10.68 ± 1.95 < 0.001a
 Height SDS
  Baseline − 2.39 ± 0.37 − 2.37 ± 0.58
  Week 26 − 2.32 ± 0.43 − 1.75 ± 0.67
  Week 26-base-
line
0.06 ± 0.15 0.63 ± 0.16 < .001a
  p value 0.033c < 0.001c
 Weight SDS
  Baseline − 1.98 ± 0.68 − 2.16 ± 1.20
  Week 26 − 1.91 ± 0.70 − 1.47 ± 1.04
  Week 26-base-
line
0.06 ± 0.28 0.64 ± 0.46 < 0.001a
  p value 0.228c < 0.001c
 Body mass index SDS
  Baseline − 0.51 ± 0.91 -0.68 ± 1.01
  Week 26 − 0.56 ± 0.89 -0.48 ± 0.90
  Week 26-base-
line
− 0.03 ± 0.32 0.12 ± 0.52 0.152a
  p value 0.597c 0.177c
 Bone Age (year)
  Baseline 5.63 ± 2.66 5.11 ± 1.84
  Week 26 6.06 ± 2.75 5.48 ± 1.91
  Week 26-base-
line
0.37 ± 0.41 0.39 ± 0.41 0.836b
  p value < 0.001d < 0.001d
 IGF-1 (ng/mL)
  Baseline 112.44 ± 49.49 101.16 ± 42.34
  Week 26 124.96 ± 54.33 257.61 ± 83.63
  Week 26-base-
line
12.54 ± 29.95 153.34 ± 67.60 < 0.001a
  p value 0.027c < 0.001d
 IGFBP-3 (ng/mL)
  Baseline 3.29 ± 0.83 3.23 ± 0.83
  Week 26 3.90 ± 0.89 4.89 ± 0.74
  Week 26-base-
line
0.62 ± 0.87 1.65 ± 0.76 < 0.001a
  p value < 0.001d < 0.001c
Table 3  Change in annual height velocity from week 0 to week 52 in 
the treatment and control groups
a Paired t test was used for within-group comparisons
b Two sample t test was used for between-group comparisons
Group Control (n = 32) Treatment (n = 36) p value
Height (cm)
 Week 0 109.24 ± 12.26 107.61 ± 9.69
 Week 26 112.45 ± 11.99 112.79 ± 9.45
 Week 52 117.79 ± 11.88 117.33 ± 9.54
Annualized height velocity (cm/year) at week 26 and week 52 in the 
treatment group
 Week 0–26 10.93 ± 1.64
 Week 0–52 10.17 ± 1.23
 p value < 0.001a
Annual height velocity at week 52 in the treatment group, and after 
weeks 27–52 in the control group
 Week 27–52/
week 0–52
10.48 ± 1.70 10.17 ± 1.23 0.423b
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0.21 ± 0.54 ng/mL in the control group and 0.30 ± 0.35 ng/
mL in the treatment group, with no statistically significant 
difference between the two groups (p = 0.658). Vital signs 
and concomitant medication did not show statistically sig-
nificant differences between the groups. The safety results of 
the control and treatment groups, during the 26 weeks and 
at follow-up, were similar.
Discussion
In this study, GH therapy applied to Korean children with 
ISS resulted in a significant increase in annual height veloc-
ity (10.68 ± 1.95 cm/year) and mean Ht SDS (0.63 ± 0.16) 
after 6 months. In addition, the annual increase in height 
was 10.17 ± 1.95 cm/year during the first year. No clinically 
relevant differences, from baseline to the end of the trial, 
were observed between the treatment and control groups 
on physical examination of vital signs, BA, or laboratory 
test results.
The efficacy results of this study are similar to those of 
previous studies [8, 11, 12]. The previous studies showed 
significantly increased growth velocity in the first year of 
treatment (7–9 cm/year, compared to 4–5 cm/year before 
treatment), and a difference in height velocity between treat-
ment and control (or placebo) groups of approximately 2 cm/
year [11]. The mean Ht SDS of the treatment group also 
exceeded that of the control group, by 0.60 SDS [8].
One short-term, uncontrolled study of Korean children 
with ISS treated with  Eutropin® (Korean product, LG 
Chem.) was published in 2014 [12]. Compared to the cited 
study, we enrolled approximately twice as many subjects, 
Table 4  Adverse events by 
system organ class (weeks 
0–52)
System organ class Number of subjects (%) [number of events]
Control (n = 31) Treatment (n = 36)
Blood and lymphatic system disorders 1 (2.8) [1]
Eye disorders 1 (2.8) [1]
Gastrointestinal disorders 5 (16.1) [7] 5 (13.9) [8]
General disorders and administration site conditions 2 (6.5) [2] 5 (13.9) [5]
Immune system disorders 1 (3.2) [1] 3 (8.3) [3]
Infections and infestations 18 (58.1) [56] 17 (47.2) [50]
Injury, poisoning and procedural complications 3 (9.7) [3]
Investigations 1 (2.8) [1]
Nervous system disorders 1 (3.2) [1] 1 (2.8) [1]
Respiratory, thoracic and mediastinal disorders 3 (8.3) [5]
Skin and subcutaneous tissue disorders 3 (8.3) [3]
Surgical and medical procedures 1 (3.2) [1]
Table 5  Laboratory results 
at baseline and week 26 in the 
treatment and control groups
ALP alkaline phosphatase, hGH human growth hormone, TSH thyroid stimulating hormone
Control (n = 31) Treatment (n = 36)
N Mean ± SD N Mean ± SD
ALP (IU/L) Baseline 31 282.3 ± 179.53 36 308.6 ± 187.27
Week 26 29 305.7 ± 197.19 32 357.0 ± 221.52
Cholesterol (mg/dL) Baseline 31 166.7 ± 27.01 36 178.0 ± 29.07
Week 26 29 169.9 ± 27.38 32 172.1 ± 25.26
Triglyceride (mg/dL) Baseline 31 88.48 ± 40.26 36 94.03 ± 60.10
Week 26 29 100.3 ± 53.51 31 112.8 ± 73.35
Hemoglobin A1c (%) Baseline 31 5.35 ± 0.30 36 5.30 ± 0.26
Week 26 29 5.37 ± 0.27 32 5.40 ± 0.23
TSH (mIU/L) Baseline 31 3.02 ± 1.53 36 3.01 ± 1.54
Week 26 31 2.70 ± 1.59 33 2.66 ± 2.16
Free thyroxine (ng/dL) Baseline 31 1.29 ± 0.21 36 1.33 ± 0.23
Week 26 31 1.29 ± 0.18 33 1.37 ± 0.33
Anti-hGH antibody Baseline 31 0.29 ± 0.43 36 0.24 ± 0.15
Week 26 31 0.50 ± 0.44 33 0.51 ± 0.34
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and analyzed the efficacy and safety of GH therapy over a 
longer treatment period.
Several studies suggested that long-term GH treatment 
increases adult height [1, 3, 13]. It has already been reported 
that GH therapy using rhGH, such as  Humatrope® (Eli Lilly) 
[14] or  Genotropin® (Pfizer) [15], increases final height in 
children with ISS. Previous reports suggest that the height 
outcome in ISS depends on the age at the start of the treat-
ment and baseline Ht SDS [16, 17]. Children with ISS may 
have a short stature due to reduced sensitivity to GH, despite 
a normal GH concentration, and inherently defective sen-
sitivity to GH may be ameliorated by administering GH at 
a dose higher than the recommended dose for GHD. Wit 
et al. suggested that the GH dose chosen for the first year of 
therapy has a significant impact on the final Ht SDS, with a 
dose of 0.37 mg/kg/week being more effective than a dose of 
0.24 mg/kg/week [18]. In a recent study, the 2-year efficacy 
of GH therapy demonstrated that high- or standard-dose GH 
treatment groups grew to within the normal range (mean Ht 
SDS, –1.4); overall, most of the subjects (83%) reached the 
normal range [19]. Therefore, early treatment of GH with 
supraphysiological doses appears to produce the greatest 
increases in adult height [15, 18].
In this study, the safety profile for the doses of GH 
employed during 1  year was generally consistent with 
what would be expected for a pediatric population: only 
well-known adverse events associated with GH treatment 
occurred, and no new safety concerns emerged [20, 21]. In 
evaluating the growth response of the treatment group, it was 
reassuring that the GH treatment with the FDA-approved 
dose for ISS had a good safety profile [22]. Mean blood 
glucose and glycosylated hemoglobin levels did not change 
during treatment, and there was no case of diabetes in either 
group. Therefore, the influence of GH on carbohydrate 
metabolism was similar to that found in previous studies 
on patients with ISS [14, 18, 23]. There was a significant 
difference in serum IGF-I levels between the treatment and 
control groups; however, increased IGF-1 levels were within 
the normal range using age-appropriate reference standards. 
Previous studies did not find any evidence that GH treat-
ment using the FDA-approved doses for ISS influences the 
onset of puberty, or enhances pubertal development [24]. 
The change in mean BA was similar in male and female 
subjects, across all groups, throughout this trial. The safety 
outcomes of both the control and treatment groups, during 
both the 26-week study period and follow-up, were similar to 
those of previous studies [3, 20]. The long-term safety of GH 
has not been clearly shown. The Safety and Appropriateness 
of Growth Hormone Treatments in Europe (SAGhE) study 
found that mortality increased in adults treated with rhGH as 
children, particularly in those who had received more than 
50 μg/kg/day of GH; mortality caused by bone tumors or 
cerebral hemorrhage was of most concern [22]. However, the 
GH dosage of the present study did not exceed 50 μg/kg/day 
and we encountered no short-term mortality (1 year), and 
no bone tumor or cerebral hemorrhage. Additional, longer 
follow-up studies are needed.
In conclusion, the analysis undertaken in this study dem-
onstrates that GH treatment can increase the height velocity 
and Ht SDS of children with ISS, and there was no signifi-
cant difference in safety between the treatment and control 
groups. Further studies should be conducted to determine 
the optimal criteria for ISS treatment, and to evaluate effi-
cacy and safety over the long term.
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